Showing results (321-330 of 374) with videos related to
Sort By:
Pageof 38
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.Clinical Lymphoma, Myeloma & Leukemia|March 23, 2024
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple MyelomaRahul Banerjee, Andrew J Cowan, Marivel Ortega, et al.Journal of the American Chemical Society|October 27, 2015
Gelation Landscape Engineering Using a Multi-Reaction Supramolecular Hydrogelator SystemJamie S Foster, Justyna M Żurek, Nuno M S Almeida, et al.Blood Cancer Journal|June 18, 2025
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working GroupXinyan Lu, Erica F Andersen, Rahul Banerjee, et al.Journal of the American Chemical Society|July 6, 2023
Nuclear Resonance Vibrational Spectroscopy Definition of Peroxy Intermediates in Catechol Dioxygenases: Factors that Determine Extra- versus Intradiol CleavageJeffrey T Babicz, Melanie S Rogers, Dory E DeWeese, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myelomaMartha Q Lacy, Suzanne R Hayman, Morie A Gertz, et al.Channels (Austin, Tex.)|July 16, 2015
A rendezvous with the queen of ion channels: Three decades of ion channel research by David T Yue and his Calcium Signals LaboratoryIvy E Dick, Worawan B Limpitikul, Jacqueline Niu, et al.Future Oncology (London, England)|April 23, 2026
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studiesRahul Banerjee, Meera Mohan, Bhavesh Shah, et al.Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.Pageof 38